Indirect Annuloplasty to Treat Functional Mitral Regurgitation: Current Results and Future Perspectives

Tiffany Patterson1,*, Heath Adams2, Christopher Allen1, Ronak Rajani1, Bernard Prendergast2 and Simon Redwood1

1 Cardiovascular, King’s College London, St. Thomas Hospital, London, United Kingdom, 2 Cardiovascular, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom

The incidence of mitral regurgitation (MR) is approximately 1.7% in the developed world, and this increases to more than 10% in patients aged over 75 years. Functional (or secondary) mitral regurgitation (FMR) is defined as poor leaflet coaptation and tethering secondary to either ischemic or non-ischemic left ventricular (LV) dysfunction and dilatation. FMR is more common than degenerative (or primary) MR and is associated with significantly worse outcomes in patients with heart failure, post myocardial infarction and following coronary artery bypass graft surgery. Patients with severe degenerative MR have excellent outcomes with surgical repair, however the benefits of surgery in FMR are less clear. Although annuloplasty is associated with a lower operative mortality compared to replacement, the recurrence rate of mitral regurgitation is high in patients with FMR and neither surgical repair or replacement have been shown to reduce hospitalisation or death in FMR. Furthermore, nearly half of patients are deemed too high risk for surgery and therefore most patients are managed conservatively and there remains an unmet clinical need. Transcatheter mitral valve interventions are an emerging alternative for those at high surgical risk. This mini review focuses on indirect mitral annuloplasty: anatomical considerations, patient selection, current devices, implantation techniques and the associated clinical outcome data.

Keywords: mitral regurgitation, annuloplasty, transcatheter, functional mitral regurgitation, indirect annuloplasty

BACKGROUND

The incidence of mitral regurgitation (MR) is ~1.7% in the developed world, and this increases to more than 10% in patients aged over 75 years (1). Functional (or secondary) mitral regurgitation (FMR) is defined as poor leaflet coaptation and tethering secondary to either ischemic or non-ischemic left ventricular (LV) dysfunction and dilatation. FMR is more common than degenerative (or primary) MR and is associated with significantly worse outcomes in patients with heart failure, post myocardial infarction and following coronary artery bypass graft surgery (2–4). Patients with severe degenerative MR have excellent outcomes with surgical repair, however the benefits of surgery in FMR are less clear (5, 6).
Current guidelines for the management of severe FMR recommend consideration of surgical intervention (repair or replacement) in symptomatic patients only following optimization of medical treatment ± cardiac resynchronization therapy (7, 8). Although annuloplasty is associated with a lower operative mortality compared to replacement, the recurrence rate of mitral regurgitation is high in patients with FMR and neither surgical repair or replacement have been shown to reduce hospitalization or death in FMR (5, 6, 9). Furthermore, nearly half of patients are deemed too high risk for surgery and therefore most patients are managed conservatively and there remains an unmet clinical need (10). Transcatheter mitral valve interventions are an emerging alternative for those at high surgical risk. These treatments are rapidly evolving with a number of novel transcatheter mitral techniques now available, many of which mimic surgical repair. Due to the complexity of the mitral valve apparatus, various techniques have been designed to target certain aspects of failure of the mitral apparatus. As FMR is predominantly a disease of the LV with failure of leaflet coaptation, the aim is to reduce the septal-lateral distance of the mitral annular plane and/or increase coaptation of the leaflets. Transcatheter annuloplasty techniques serve to reduce annular dimensions and differ from surgical techniques in that they provide the option of both direct and indirect approaches (11–15), each of which have their own potential advantages. Direct annuloplasty enables closer approximation to the mitral valve, whereas indirect annuloplasty is potentially a much simpler procedure. This mini review focuses on indirect mitral annuloplasty: anatomical considerations, patient selection, current devices, implantation techniques, and the associated clinical outcome data.

ANATOMICAL CONSIDERATIONS FOR INDIRECT ANNULOPLASTY

The coronary sinus (CS) drains the majority of blood from the heart. It arises from the termination of the great cardiac vein, running through the left atrioventricular groove, emptying into the right atrium. The CS lies in close anatomical proximity to the mitral annulus (Figure 1A) (16). Indirect annuloplasty therefore utilizes the CS to exert a constraining force on the mitral annulus, thereby decreasing its septal-lateral diameter, improving leaflet coaptation and reducing the degree of mitral regurgitation. However, anatomical variation between individuals may limit the clinical efficacy of this approach. Indirect annuloplasty relies on the proximity of the CS to the mitral annulus—however, the CS is located superior to the mitral annulus in a significant number of patients and is often higher posteriorly than anteriorly (17). Furthermore, the distance between the mitral annulus and CS tends to increase in patients with dilated ventricles and severe MR (18). This could therefore explain the variation in clinical efficacy amongst different indirect annuloplasty devices.

Importantly, the circumflex coronary artery lies within close proximity of both the CS and mitral annulus. Studies have demonstrated that the vessel exhibits a deep course between the CS and mitral annulus in up to two thirds of patients (19, 20). There is therefore a theoretical risk of compression and myocardial infarction associated with indirect annuloplasty. Accurate pre-procedural imaging assessment of the venous system, coronary sinus anatomy, and mitral annular plane is essential to determine suitability and ensure appropriate patient selection prior to device implantation.

PATIENT SELECTION FOR ANNULOPLASTY TECHNIQUES

The complexity of the mitral valve apparatus necessitates patient-specific tailoring using the appropriate reparative technique because no single transcatheter technology “fits-all.” Assessment of suitability prior to annuloplasty is crucial and decision with regard to repair technique should be based on clinical and anatomical characteristics. When selecting the appropriate transcatheter therapy, it is important to first establish the primary mechanism of MR, its severity and the imaging criteria that will predict procedural success. Traditionally, annuloplasty, either with direct or indirect percutaneous techniques are favored where annular dilatation is the predominant pathology. Surgical features of annuloplasty failure should also be taken into consideration, these include but are not limited to, increased annular dimensions (≥3.7 cm), increased systolic tenting height, complex jet(s) of mitral regurgitation and lateral wall motion abnormalities (21, 22). Furthermore anatomical considerations including the position of the CS in relation to the mitral annulus and position of the coronary arteries must also be taken into consideration. In Table 1 we summarize the clinical and echocardiographic criteria for the currently available indirect annuloplasty techniques and the comparable reduction in MR from the respective clinical trials and compare these to direct annuloplasty and edge-to-edge repair. Edge-to-edge repair may be the preferred initial therapy in FMR if the predominant mechanism of failure of coaptation is leaflet tethering or prolapse, as can be the case with ischemic MR, where leaflet tethering and annular dilatation can coexist. Percutaneous edge-to-edge repair joins the anterior and posterior leaflets using a clip, mimicking the surgical Alfieri technique and can be used in the treatment of both degenerative and FMR (25–27). Edge-to-edge repair has been shown to improve clinical outcomes in FMR with a greater benefit shown with increasing MR severity (23). Recent randomized trial data in favor of edge-to-edge repair in FMR would suggest a greater benefit in patients with severe heart failure symptoms (NYHA III-IV), larger regurgitant volume, with smaller LV end-diastolic dimensions (23, 28). However, assessment of patient suitability for edge-to-edge repair is necessary (Table 1) and increased severity of MR may necessitate more than one clip. The surgical Alfieri technique is often performed in conjunction with annuloplasty, as such there may be scope for performing combined transcatheter mitral interventions in these patients (see Figure 1B). Although this is yet to be demonstrated on a larger scale, reports of indirect or direct annuloplasty following edge-to-edge repair demonstrate reasonable outcomes. However, there is theoretical risk of mitral
valve outflow obstruction with more than one device, thus more data are required if there is to be a role for this in the future.

**CARILLON DEVICE**

The Carillon coronary sinus implant (Cardiac Dimensions) is currently the only CE approved indirect annuloplasty device undergoing clinical use. The main advantage is its simplicity and safety profile, and more than 700 procedures have been performed worldwide to date (29). The Carillon device is a fixed length nitinol system that is delivered to the CS via a 9 French delivery system through the right external jugular vein (Figure 1C) (30). The device is comprised of a distal and proximal anchor. The distal anchor is deployed deep in the CS encircling the mitral annulus and traction is applied thereafter through foreshortening of the central nitinol element, thus constricting the coronary sinus by cinching the posterior peri-annular tissue and reducing mitral annular dimensions. Following confirmation of reduced mitral annular dimensions, a check angiogram is performed to ensure circumflex patency prior to final device release.

Two clinical trials of safety and feasibility have been conducted to date. The Carillon Mitral Annuloplasty Device European Union Study (AMADEUS) study successfully implanted devices in two thirds of patients selected to undergo the procedure. Patients in the AMADEUS study had only modest reductions in MR at 6-month follow up (14). The Transcatheter Implantation of Carillon Mitral Annuloplasty Device (TITAN) trial, 36 patients underwent device implantation and 17 had the device recaptured, the latter were used as a comparator group. There was no difference in the composite safety endpoint and the reduction in MR was more significant in the cohort that received the device, with an average decrease in regurgitant volume of 17 ml. This was accompanied by a significant reduction in LV systolic and diastolic dimensions at 12 and 24 months following successful implantation (31).

More recently, the outcomes of the REDUCE-FMR trial of efficacy and safety of Carillon implantation vs. sham control in patients with functional MR secondary to dilated ischemic or non-ischemic cardiomyopathy have been presented (24). The primary efficacy outcome of reduction in mitral regurgitant volume at 1 year was met (−7.1 vs. 3.3 ml; P = 0.03), the numerical reduction of MR was even more notable in the per protocol analysis (−12.5 vs. 1.3 ml; p = 0.06). Furthermore, no significant difference in major adverse cardiovascular and cerebrovascular events was demonstrated between the Carillon and sham control cohort. The CARILLON FDA trial (NCT03142152) of 450 patients randomized to the CARILLON device with optimal heart failure therapy vs. optimal heart failure therapy alone is currently open to recruitment in the United States.
| Technique | Device | Indication | Trial & design | Number of patients | Imaging & clinical inclusion criteria | Mean reduction in RV (mL) | CE mark |
|-----------|--------|------------|----------------|-------------------|---------------------------------------|--------------------------|---------|
| Indirect annuloplasty | Carillon | Secondary/FMR with annular dilatation | AMADEUS phase I safety trial | 48 (30 received device) | Moderate or severe FMR, EF < 40%, NYHA class II–IV symptoms | −8.8 (6 months), \( P < 0.001 \) | YES |
| | | | TITAN prospective non-randomized multicentre trial | 53 (36 received the device) | Moderate or severe FMR, EF < 40%, NYHA class II–IV symptoms despite OHFT, 6-min walk 150–450 m | −17 ± 12 (1 year), \( P < 0.001 \) | |
| | | | REDUCE FMR sham control trial | 87 device groups vs. 33 sham procedure | Moderate or severe FMR, EF < 50%, NYHA class III–IV symptoms despite OHFT, LVEDD > 55 mm | −7.1 vs. + 3.3 controls (1 year), \( p = 0.03 \) | |
| ARTO | | Secondary/FMR with annular dilatation | MAVERIC phase I safety trial | 11 | Moderate or severe FMR, EF < 40%, LVEDD > 50 mm & ≤ 75 mm | −25.9 (30-days), \( p = \text{NS} \) | NO |
| Mitral Loop Cerclage System | | Secondary/FMR with annular dilatation | Phase 1 trial | 5 | Severe FMR (RV ≥ 30 mL, RF ≥ 50 mL, EROA ≥ 0.20 cm\(^2\)), NYHA class III–IV despite OHFT | −36.3 (6 months), \( p = \text{NS} \) | NO |
| Direct annuloplasty | Cardioband (Edwards Lifesciences, California, USA) | Secondary/FMR with annular dilatation | Single-arm, multicenter prospective trial | 31 | Severe FMR despite OHFT including CRT | −11.4 (6 months), \( p = 0.063 \) | YES |
| Edge to edge repair | MitraClip (Abbott Vascular, Illinois, USA) | Primary degenerative (FDA approved) and ischemic MR (secondary) with annular dilatation | COAPT Randomized controlled open label trial | 302 device vs. 312 control (OHFT) | Moderate to severe FMR despite OHFT, EF 20–50%, LVEDD ≤ 70 mm NB: more than one clip or alternative to be considered if flail width > 15 mm, gap > 10 mm, coaptation depth > 11 mm; not suitable for rheumatic or bileaflet flail | NS, however < moderate MR in 94.8% vs. 46.9% controls, \( P < 0.001 \) | YES |

Nickenig et al. (11), Stone et al. (23), Goldberg et al. (24) CRT, cardiac resynchronization therapy; EF, ejection fraction; EROA, effective regurgitant orifice area; FMR, functional mitral regurgitation; LVEDD, left ventricular end diastolic diameter; NS, not specified; NYHA, New York heart association; OHFT, optimal heart failure therapy; RF, regurgitant fraction; RV, regurgitant volume.
ARDO DEVICE

The ARTO system (MVRx Inc., Belmont, CA, USA) is comprised of two anchors deployed over the lateral wall of the left atrium via the CS and in the atrial septum, connected by a tether that traverses the left atrial chamber (Figure 1D). Erglis et al. (15) Implantation is performed using transesophageal echocardiographic guidance with the patient under general anesthetic. Two venous access sites are required to deliver the device. One of two magnetic catheters is positioned in the coronary sinus over the lateral wall of the left atrium through right jugular venous access. The second magnetic catheter is positioned across the atrial septum via femoral venous access and trans-septal puncture. These two catheters are then manipulated and linked magnetically in the posterior left atrium adjacent to the posterior mitral annulus. A small puncturing wire is then used to create a connection between the two magnetic catheters. Routine catheter exchanges are performed to deliver a coronary sinus anchor (T-bar) and atrial septal anchor, connected by a suture whose length can be adjusted to reduce the anteroposterior (AP) diameter of the mitral annulus until an acceptable reduction in MR is achieved. This suture is then locked and cut.

In the first phase of the MitrAl ValVe Repair Clinical (MAVERIC) trial, 11 patients underwent successful device implantation with one device displacement and one pericardial effusion requiring surgical intervention. At 30-day follow up, a decrease in regurgitant volumes from 45.4 ± 15.0 ml to 19.5 ± 10.2 ml was demonstrated with a beneficial effect on LV volumes. LV end-systolic volume index improved from 77.5 ± 24.3 ml/m² to 68.5 ± 21.4 ml/m², and LV end-diastolic volume index from 118.7 ± 28.6 ml/m² to 103.9 ± 21.2 ml/m². Mitral annular AP diameter decreased from 45.0 ± 3.3 mm to 38.7 ± 3.0 mm with an associated improvement in New York Heart Association (NYHA) functional class (32). Data at 2-year follow up demonstrated a consistent significant improvement in functional MR grade, regurgitant volumes (39.1 ± 11.6 ml vs. 14.0 ± 10.3 ml; p < 0.001) and reduction in mitral annular AP diameter (45.9 ± 3.1 mm vs. 39.8 ± 3.3 mm; p < 0.001). These changes were associated with an improvement in symptomatic status from 81.8% NYHA functional class III/IV at baseline to 60.0% NYHA functional class I/II at 2 years (33). Phase II of the MAVERIC trial is ongoing with 34 patients enrolled at 8 sites.

MITRA LOOP CERCLAGE SYSTEM

The Mitral Loop Cerclage annuloplasty system (Tau-PNU Medical Co, Ltd.) consists of a stainless-steel tension element delivered using a multistep procedure to form a continuous loop from the coronary sinus to a basal septal perforator coronary vein and right ventricular outflow tract (Figure 1E) (13). It has a coronary sinus tricuspid bridge device (that straddles and protects the septal tricuspid leaflet and coronary conduction system) completing the loop. There is an arch-like coronary artery protection element to prevent compression of the circumflex and the device can be tensioned in real-time under echocardiographic guidance to titrate the indirect annuloplasty.

Implantation is performed under moderate sedation (transthoracic echocardiogram) or general anesthesia (transesophageal echocardiogram). Access is via 19 Fr sheaths in the left subclavian and right femoral vein. A dual lumen coronary sinus guiding catheter is introduced into the coronary sinus via the left subclavian and contrast injection used to identify a basal septal perforator vein through which a stiff tipped peripheral guidewire is introduced and used to traverse the septum into the right ventricular outflow tract before snaring into the femoral vein. The tension element is then connected to the guidewire using heat-shrink tubing and pulled into position through the CS into the interventricular septum before loop snaring of the distal guide wire tip from the femoral vein into the subclavian. Next, the bifid coronary sinus tricuspid valve bridge is advanced over the two free ends of the tension element and the coronary artery protection element positioned with diagnostic angiography. Tension is then applied to reduce the septal lateral distance and the tension device is locked and embedded in the subclavian pocket.

First in human results demonstrate successful implantation in 4 out of 5 patients. Failure to implant in one was due to unsuitable anatomy. Of those who underwent successful implantation, one patient suffered myocardial infarction and one patient died of refractory heart failure at 6 weeks. All patients demonstrated an immediate reduction in regurgitant volume. At 6-month follow up, regurgitant volume continued to decrease in the remaining 3 patients and was associated with a reduction in left atrial and LV systolic and diastolic size. Interestingly, two patients reverted to sinus rhythm at the end of the procedure (34). This was speculated to be secondary to electrical remodeling induced by the cerclage device, but may also be as a result of reduced cardiac dimensions.

FAILED INDIRECT ANNULOPLASTY DEVICES

Coronary sinus constriction can lead to complex torsional deformation due to the complexity of the mitral annular plane and position of the CS in relation to the mitral annulus. This has unfortunately led to the failure of two previously developed devices despite encouraging early clinical safety and feasibility data (35, 36). The Viacor Percutaneous Transvenous Mitral Annuloplasty (PTMA) device comprised nitinol rods positioned in the CS to compress the posterior mitral annulus—however, device fracture in one patient led to a late, fatal coronary sinus laceration and removal from clinical use. The MONARC device (Edwards LifeSciences) was a spring-like band deployed in the coronary sinus with two self-expanding stents at either end (36). However, this device is also no longer in use due to a number of reported fractures between the band and the stents.

FUTURE DIRECTIONS AND LIMITATIONS

Functional MR is an unmet clinical need in those on maximal medical therapy but considered too high risk for conventional
surgery. Annuloplasty techniques and the associated data are promising. However, annuloplasty techniques may not be suitable for all patients. Anatomical variation between individuals may limit the clinical efficacy of this approach as indirect annuloplasty relies on the proximity of the CS to the mitral annulus. Increasing LV dilatation further increases the distance between the mitral annulus and CS potentially rendering this approach ineffective. The reduction in annular dimensions from percutaneous interventions have not been as large as suggested in the surgical literature and longer-term clinical data are required to ensure safety and efficacy of these devices due to the risk of device erosion and coronary occlusion and also to assess for recurrence of MR.

The recent results of the MITRA-FR and COAPT trial have helped define a patient population in whom there is potential benefit from MitraClip implantation (Table 1). The surgical Alfieri technique is frequently performed in conjunction with annuloplasty, and there may be scope for performing combined transcatheter mitral repair in these patients, however this is yet to be demonstrated on a larger scale. It would be advisable for centers providing transcatheter mitral interventions to be trained in a number of techniques so as to appropriately select the patient cohort that would benefit from a specific technique. An increased appreciation of the mitral valve apparatus will no doubt aid development of further novel mitral technologies and second and third generation devices are anticipated to improve procedural safety and success rates. Such devices will require large scale clinical validation and Heart Team involvement will be essential to determine patient suitability. Due to the complexity of the mitral valve apparatus, Heart Team decision making will require evaluation of patient-specific anatomical characteristics using novel imaging techniques, including 3D TEE and CT image fusion (Figures 2A–F). This will aid decision-making and guide periprocedural planning and implantation to ensure successful procedures with minimal complications.

CONCLUSIONS

An increase in anteroposterior (AP) mitral annular diameter is the common final pathway in the development of functional MR and associated with worsening clinical outcomes in heart failure and post myocardial infarction. Shortening of the AP dimension is therefore critical to alleviating MR. The aim of transcatheter mitral repair is to balance the increase in periprocedural safety (reduced risk) with a sufficient reduction in MR for it to be effective. Annuloplasty, both direct and indirect,
leaflet repair and chordal repair are all viable options based upon well-established surgical techniques and a combination of these approaches may provide the most effective resolution of MR. Current predictors of MR recurrence following surgical repair include baseline LV end-diastolic diameter >65 mm, posterior mitral leaflet angle >45 degrees and mitral coaptation depth >10 mm (37). However, the relevance of these for the success of percutaneous interventions remains unknown. Furthermore, there are numerous challenges to effective treatment of MR, including anatomical variation and the complexity of the mitral valve apparatus, imaging constraints and currently available technologies. There remain important considerations when determining suitability for percutaneous mitral valve interventions, including appropriate patient selection (moderate vs. severe MR, normal vs. impaired LV function) and choice of device based on anatomical characteristics. Although further work is required to ensure safety and durability of these devices, increased understanding of the true incidence, natural history and pathophysiology of MR, will enable better targeted device therapy in this cohort.

AUTHOR CONTRIBUTIONS

SR manuscript conception, design, and critical revision. BP manuscript critical revision. RR manuscript critical review and revision. TP manuscript conception, design and critical revision. HA critical revision of the manuscript. CA critical revision of the manuscript.

REFERENCES

1. D’Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stutard J, Birks J, et al. Large-scale community echocardiographic screening reveals a major burden of undiagnosed valvular heart disease in older people: the OxValVE population cohort study. Eur Heart J. (2016) 37:3515–22. doi: 10.1093/eurheartj/ehw229
2. Grossi EA, Crooke GA, DiGiorgi PL, Schwartz CF, Jorde U, Applebaum RM, et al. Impact of moderate functional mitral insufficiency in patients undergoing surgical revascularization. Circulation. (2006) 114(1 Suppl);1573–6. doi: 10.1161/CIRCULATIONAHA.105.001230
3. Robbins JD, Maniar PB, Cotts W, Parker MA, Bonow RO, Gheorghide M. Prevalence and severity of mitral regurgitation in chronic systolic heart failure. Am J Cardiol. (2003) 93:360–2. doi: 10.1016/S0002-9149(02)03172-7
4. Bursi F, Enriquez-Sarano M, Nkomo VT, Jacobsen SJ, Weston SA, Meverden 45 degrees and mitral coaptation depth >65 mm, posterior
5. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. (2017) 70:252–89. doi: 10.1016/j.jacc.2017.03.011
6. Stone GW, Vahanian AS, Adams DH, Abraham WT, Borer JS, Bax JJ, et al. Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part I: clinical trial design principles. J Am Coll Cardiol. (2015) 66:278–307. doi: 10.1016/j.jacc.2015.05.046
7. Mirabel M, Jung B, Baron G, Messika-Zeitoun D, Detaint D, Vanoverschelde JL, et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery? Eur Heart J. (2007) 28:1358–65. doi: 10.1093/eurheartj/ehm001
8. Falk V, Baumgartner H, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur J Cardiothorac Surg. (2017) 52:616–64. doi: 10.1093/ejcts/ezx127
9. Acker MA, Parides MK, Perraup LT, Moskowitz AJ, Gelijns AC, Voisine P, et al. Mitral-valve repair versus replacement for severe ischaemic mitral regurgitation. N Engl J Med. (2013) 370:23–32. doi: 10.1056/NEJMoa1312808
10. Goel SS, Bajaj N, Agarwal B, Gupta S, Poddar KL, Ige M, et al. Prevalence and outcomes of unoperated patients with severe symptomatic mitral regurgitation and heart failure. J Am Coll Cardiol. (2014) 63:185–6. doi: 10.1016/j.jacc.2013.08.723
11. Nickenig G, Schueler R, Dager A, Martinez Clark P, Abizaid A, Siminiak T, et al. Treatment of chronic functional mitral valve regurgitation with a percutaneous annuloplasty system. J Am Coll Cardiol. (2016) 67:2927–36. doi: 10.1016/j.jacc.2016.03.391
12. Miasano F, Taramasso M, Nickenig G, Hammerstingl C, Vahanian A, Messika-Zeitoun D, et al. Cardioband, a transcatheter surgical-like direct mitral valve annuloplasty system: Early results of the feasibility trial. Eur Heart J. (2016) 37:817–25. doi: 10.1093/eurheartj/ehw603
13. Kim J-H, Kocaturk O, Ozturk C, Faramesh AZ, Sonmez M, Sampath S, et al. Mitral cerclage annuloplasty, a novel transcatheter treatment for secondary mitral valve regurgitation: initial results in swine. J Am Coll Cardiol. (2009) 54:638–51. doi: 10.1016/j.jacc.2009.03.071
14. Schofer J, Siminiak T, Haude M, Herrman JP, Vainer J, Wu JC, et al. Percutaneous mitral annuloplasty for functional mitral regurgitation: Results of the CARILLON mitral annuloplasty device European union study. Circulation. (2009) 120:326–33. doi: 10.1161/CIRCULATIONAHA.109.849885
15. Erglis A, Thomas M, Morice M-C, Narbute I, Zabunova M, Hovasse T, et al. The Arto transcatheter mitral valve repair system. EuroIntervention. (2015) 11(Suppl W):W47–8. doi: 10.4244/EIJ15WA12
16. El-Maasarany S, Ferret GD, Firth A, Sheppard M, Henlein MY. The coronary sinus conduit function: anatomical study (relationship to adjacent structures). Euro.Heart. (2005) 7:475–81. doi: 10.1002/ijrcp.2005.05.013
17. Choure AJ, Garcia MJ, Hesse B, Sevensma M, Maly G, Greenberg NL, et al. In Vivo analysis of the anatomical relationship of coronary sinus to mitral annulus and left circumflex coronary artery using cardiac multidetector computed tomography. Implications for percutaneous coronary sinus mitral annuloplasty. J Am Coll Cardiol. (2006) 48:1938–45. doi: 10.1016/j.jacc.2006.07.043
18. Lee MS, Shah AP, Dang N, Berman D, Forrest J, Shah PK, et al. Coronary sinus is dilated and outwardly displaced in patients with mitral regurgitation: quantitative angiographic analysis. Catheter Cardiovasc Interv. (2006) 67:490–4. doi: 10.1002/ccd.20616
19. Tops LF, Wood DA, Delgado V, Schuif JD, Mayo JR, Pasupati S, et al. Noninvasive evaluation of the aortic root with multislice computed tomography. implications for transcatheter aortic valve replacement. JACC Cardiovasc Imaging. (2008) 1:321–30. doi: 10.1016/j.jcmg.2007.12.006
20. Maselli D, Guarracino F, Chiaramonti F, Mangia F, Borelli G, Minzioni G. Percutaneous mitral annuloplasty: an anatomic study of human coronary sinus and its relation with mitral valve annulus and coronary arteries. Circulation. (2006) 114:577–80. doi: 10.1161/CIRCULATIONAHA.105.609883
21. McGee EC, Gillinov AM, Blackstone EH, Rajeswaran J, Cohen G, Najam F, et al. Recurrent mitral regurgitation after annuloplasty for functional ischaemic mitral regurgitation. J Thorac Cardiovasc Surg. (2004) 128:916–24. doi: 10.1016/j.jtcvs.2004.07.037
22. Kron IL, Hung I, Overby JR, Bouchard D, Gelijns AC, Moskowitz AJ, et al. Predicting recurrent mitral regurgitation after mitral valve repair for severe ischemic mitral regurgitation. J Thorac Cardiovasc Surg. (2015) 149:752–61.e1. doi: 10.1016/j.jtcvs.2014.10.120
23. Stone GW, Lindenfeld J, Abraham WT, Kat S, Lim DS, Mishell JM, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. (2018) 379:2307–18. doi: 10.1056/NEJMoa1806640
24. Goldberg SL, Meredith I, Marwick T, Haluska BA, Lipiecki J, Siminiak T, et al. A randomized double-blind trial of an interventional device treatment of functional mitral regurgitation in patients with symptomatic congestive heart failure-Trial design of the REDUCE FMR study. Am Heart J. (2017) 188:167–74. doi: 10.1016/j.ahj.2017.02.032

25. Maisano F, La Canna G, Colombo A, Alferi O. The evolution from surgery to percutaneous mitral valve interventions. J Am Coll Cardiol. (2011) 58:2174–82. doi: 10.1016/j.jacc.2011.07.046

26. Glower DD, Kar S, Trento A, Lim DS, Bajwa T, Quesada R, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: Results of the EVEREST II study. J Am Coll Cardiol. (2014) 64:172–81. doi: 10.1016/j.jacc.2013.12.062

27. Feldman T, Kar S, Elmariah S, Smart SC, Trento A, Siegel RJ, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation 5-year results of EVEREST II. J Am Coll Cardiol. (2015) 66:2844–54. doi: 10.1016/j.jacc.2015.10.018

28. Obadia J-F, Messika-Zeitoun D, Leurent G, Iung B, Bonnet G, Piriou N, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med. (2018) 379:2297–306. doi: 10.1056/NEJMoa1805374

29. Bail DHL. Treatment of functional mitral regurgitation by percutaneous annuloplasty using the carillon mitral contour system-currently available data state. J Interv Cardiol. (2017) 30:156–62. doi: 10.1111/jocd.12370

30. Maniu CV, Patel JB, Reuter DG, Meyer DM, Edwards WD, Rihal CS, et al. Acute and chronic reduction of functional mitral regurgitation in experimental heart failure by percutaneous mitral annuloplasty. J Am Coll Cardiol. (2004) 44:1652–61. doi: 10.1016/j.jacc.2004.03.085

31. Siminiak T, Wu JC, Haude M, Hoppe UC, Sadowski J, Lipiecki J, et al. Treatment of functional mitral regurgitation by percutaneous annuloplasty: results of the TITAN Trial. Eur J Heart Fail. (2012) 14:931–8. doi: 10.1093/eurjhf/hfs076

32. Rogers JH, Thomas M, Morice MC, Narbut I, Zabunova M, Hovasse T, et al. Treatment of heart failure with associated functional mitral regurgitation using the ARTO system initial results of the first-in-human MAVERIC trial (mitral valve repair clinical trial). JACC Cardiovasc Interv. (2015) 8:1095–104. doi: 10.1016/j.jcin.2015.04.012

33. Erglis A, Narbut I, Poupineau M, Hovasse T, Kamzola G, Zvaigzne L, et al. Treatment of secondary mitral regurgitation in chronic heart failure. J Am Coll Cardiol. (2017) 70:2834–5. doi: 10.1016/j.jacc.2017.09.1110

34. Park Y-H, Chon M-K, Lederman RJ, Sung S-C, Je H-G, Choo K-S, et al. Mitral loop cerclage annuloplasty for secondary mitral regurgitation: first human results. JACC Cardiovasc Interv. (2017) 10:597–610. doi: 10.1016/j.jcin.2016.12.282

35. Sack S, Kahler P, Bilodeau I, Piérand LA, Lancellotti P, Legrand V, et al. Percutaneous transvenous mitral annuloplasty initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Interv. (2009) 2:277–84. doi: 10.1161/CIRCINTERVENTIONS.109.855205

36. Harnek J, Webb JG, Kuck KH, Tschope C, Vahanian A, Buller CE, et al. Transcatheter implantation of the MONARC coronary sinus device for mitral regurgitation. JACC Cardiovasc Interv. (2011) 4:115–22. doi: 10.1016/j.jcin.2010.08.027

37. De Bonis M, Al-Attar N, Antunes M, Borger M, Casselman F, Falk V, et al. Surgical and interventional management of mitral valve regurgitation: a position statement from the European societyof cardiology working groups on cardiovascular surgery and valvular heart disease. Eur Heart J. (2016) 37:133–9. doi: 10.1093/eurheartj/ehv322

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Patterson, Adams, Allen, Rajani, Prendergast and Redwood. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.